Comparative Pharmacology
Head-to-head clinical analysis: DIFLUCAN versus MYCELEX G.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFLUCAN versus MYCELEX G.
DIFLUCAN vs MYCELEX-G
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diflucan (fluconazole) is a triazole antifungal agent that inhibits fungal cytochrome P450 14-alpha-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability and inhibition of fungal growth.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
Oral or IV: 200-400 mg loading dose, then 100-200 mg once daily. Dose and duration depend on indication.
Clotrimazole 100 mg vaginal tablet inserted intravaginally once daily for 7 days or 200 mg once daily for 3 days; or 500 mg single dose. Also available as 1% vaginal cream, 1 applicatorful (5 g) intravaginally once daily for 7-14 days.
None Documented
None Documented
30 hours (range 20-50 hours); prolonged in renal impairment (up to 98 hours in CrCl <20 mL/min)
Biphasic: initial half-life ~30 minutes, terminal half-life ~30 hours; clinical significance: supports once-daily dosing for topical/vaginal formulations.
Renal: 80% unchanged; fecal/biliary: 11% as metabolites
Primarily hepatic metabolism; about 80-90% of dose excreted as metabolites in feces via biliary excretion, less than 1% unchanged in urine.
Category C
Category C
Antifungal
Antifungal